3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
6
Leukemia, Biphenotypic, Acute
2
Sarcoma, Myeloid
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid
1
Leukemia, Monocytic, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
Mitoxantrone
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled